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Africa recorded the first case of COVID-19 
on February 14, 2020, a global pandemic, the 
response to which continues to challenge 
known public health measures to effectively 
and sustainably curb the spread and magni-
tude of the epidemic.  Early in the epidemic, 
responses in most African countries were led 
by national Governments. National emergen-
cies were declared, and systems for multisec-
toral response were put in place. Strength-
ened Ministries of Health remained responsi-
ble for guiding and coordinating national and 
subnational level responses. Human, finan-
cial and material resources were leveraged 
and mobilized to equip National Public 
Health Institutes and other national entities to 
ensure health workforce training, strengthen 
diagnostic capabilities, public information, 
and disease surveillance systems, including 
expansion of non-pharmaceutical interven-
tions (NPIs).  Over the last two years, the un-
precedented social, economic, and political 
impact of COVID-19 negatively affected 
many countries. School closures, negative 
impact on businesses, reduced household in-
come, increased inflation, and logistics re-
straints (global, regional, and national level) 
created significant blows to the life of mil-
lions of Africans. The pandemic also dis-
rupted social activities, including banning re-
ligious gatherings and other social events dis-
rupting the life of communities. The COVID-
19 pandemic is expected to have devastating 
health and socioeconomic consequences in 
many countries in Africa, partly because of 
weak health systems plagued with inadequate 
surveillance and laboratory capacities. Addi-
tionally, insufficient health workforce to ef-
fectively respond to the pandemic and the 
lack of vaccines could worsen the situation 
further.  The challenge for many African 
countries remains to strike a balance between 
the gains on COVID-19 prevention, manage-
ment, and control with impacts on essential 
health services and its bearing on other non-
health impacts (social, economic, and politi-
cal).  Cognizant of this and as COVID-19 is 
expected to remain a public health threat for 
the foreseeable future and the rapidly chang-
ing epidemiology of COVID-19 variants, 
many countries are putting in place surveil-
lance systems. These are expected to help 
monitor status that could guide decision-
making in emergency preparedness and re-
sponse by implementing effective mitigating 
strategies. In this regard, the African Center 
for the Prevention and Control of Communi-
cable Diseases - the African CDC, a newly 
established Center for Disease Control under 
the African Union (AU). According to re-
ports by the African CDC it is playing an es-
sential role in supporting African countries: 
Training in emergency management and 
providing technical assistance and technol-
ogy transfer for establishing disease surveil-
lance systems at a continental level.  Such 
new procedures are intended to link with na-
tional systems to identify potential global 
health threats to prepare and respond effec-
tively. Through alliances with US CDC, aca-
demia, scientific organizations, and other 
partners, Africa CDC developed and released 
training to address priority national response 
needs; as a result, COVID-19 laboratory test-
ing capacity grew from two countries early in 
the outbreak to all 55 AU member states by 
August 2020. COVID-19 pandemic remains 
a major concern at the continental and coun-
try levels. Targeting high-risk populations 
and improving early diagnosis and treatment 
capacity are strategic approaches used to con-
trol rapidly increasing mortality rates. A new 
norm of integration of COVID-19 services 
within the essential health services system 
would reduce morbidity and mortality that 
are directly and indirectly linked to COVID-
19. However, with its weak health infrastruc-
ture and resources, the strategy of choice to 
combat the pandemic in Africa remains early 
prevention of the spread in communities. Key 
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to this has been the efforts by all countries to 
implement Non-Pharmaceutical Interven-
tions (NPIs) through increased public aware-
ness and strict adherence to the NPI norms 
and standards until vaccines are made acces-
sible to the population. Nonetheless, due to 
various socio-cultural and related factors, 
sustained adherence to the NPI standards by 
populations in most African communities has 
increasingly become difficult. Hence to com-
bat the spread of infection, urgently calls for 
accessibility of vaccines to a reasonable pro-
portion of the population in high-risk coun-
tries and communities.  Factors including the 
socio-political-economy of vaccine availabil-
ity to countries in Africa become both a 
global public health concern and an ethical 
consideration. While different companies in 
different countries produce vaccines, actual 
availability to countries in Africa has become 
increasingly difficult, calling for more active 
international solidarity. According to the re-
cent appeal by the Lancet COVID-19 Com-
mission Taskforce for Africa, the continent is 
currently experiencing the third and deadliest 
wave of the COVID-19 epidemic.  
Despite Africa’s support to COVAX, Africa 
has not been supplied with the required vac-
cines so far.  While the US now has 46% of 
its population fully vaccinated as of June 
2021, and the EU has 31 % of its population 
covered, Africa has only1.2% of its popula-
tion fully vaccinated. In total, Africa has re-
ceived just 1.6% of the vaccine doses admin-
istered worldwide, only 49 million doses out 
of the 2.9 billion doses worldwide. One could 
safely conclude that the global fight to curb 
the spread of COVID-19 could only be real-
ized with equitable global access to the vac-
cine. Vaccine coverage in Africa will benefit 
the entire global community. Would you 
please let me know any advice you may 
have on how to go about getting this very 
urgently needed vaccine to the needy pop-
ulations in Africa?  
Urgent Appeal for 300 Million Doses of 
COVID-19 Vaccines for Africa. The Lan-
cet COVID-19 Commission Africa Task 















Bishaw T. COVID -19 Pandemic - Increasing the African Access to Vaccination (Editorial.). SEEJPH 
2020, posted: 24 July 2021. DOI: 10.11576/seejph-4608 
 
P a g e  4 | 5 
 
Urgent Appeal for 300 Million Doses of COVID-19 Vaccines for Africa The Lancet 
COVID-19 Commission Africa Task Force 
June 30, 2021 
On  behalf  of  the  people  of  Africa,  we  appeal  urgently  to  the  vaccine-producing  nations  
for emergency donations and shipments of at least 300 million doses of vaccines to enable every 
country in Africa to fully immunize at least 20 percent of its adult population by end of August 
2021.1 Africa is currently experiencing the third and deadliest wave of the COVID-19 pandemic, 
driven by the highly contagious Delta Variant that was responsible for the recent devastating 
surge of disease and deaths in India. But Africa lacks vaccine protection. It has the lowest vac-
cine coverage in the world, having received just 1.6 percent of the vaccine doses administered 
worldwide until June 26 (49 million doses out of 2.9 billion doses worldwide). 
While the U.S. now has 46 percent of its population fully vaccinated (as of June 30), the Euro-
pean Union has about 33 percent, China around 40 percent, and Russia around 12 percent, Africa 
has only 1.1 percent of the population fully vaccinated. In absolute numbers, the US and Euro-
pean Union have fully vaccinated 299 million individuals compared with just 15 million in all of 
Africa, despite an African population (1.34 billion) that is 73 percent larger than the combined 
population of the US and European Union (776 million). Another 20 million Africans have re-
ceived one dose. 
We note that the scale of current production worldwide makes it now feasible to provide Africa 
with 300 million doses in the next 9 weeks on an urgent and expedited basis. We also note that 
the US has reached a near saturation in vaccine uptake, meaning that US-based production is 
now available for shipments to the rest of the world. 
We emphasize that vaccine coverage in Africa is not only for the benefit of Africa, but for the 
entire  globe.  Cases  of  COVID-19  spill  across  national  borders,  as  do  instability  and  suf-
fering from unabated epidemics. Moreover, in regions with surging infections, there are greater 
opportunities for the emergence of new and dangerous variants of the virus, as has already hap-
pened on several occasions. 
 
1We assume that 300 million doses would enable 270 million doses successfully administered. Of those, 20 million 
would constitute the second dose of the current partially immunized individuals, and 250 million doses would be for 
individuals not yet immunized, resulting in an additional 125 million fully immunized individuals. In total, 160 mil-
lion Africans would be fully immunized, accounting for 20 percent of the 800 million population aged 15 and over. 
In addition to the provision of vaccines, the international community should provide urgent fi-
nancial and technical support to the Africa CDC and to national COVID-19 control programs to 
support   non-pharmaceutical   interventions,   disease   surveillance,   diagnostics,   vaccination 
infrastructure for cold chain and vaccination stations, data management systems, and genomic 
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surveillance of breakthrough infections. Several partner countries have existing programs in Af-
rica to support infectious disease control efforts (e.g., for HIV/AIDS, malaria, and tuberculosis). 
Such programs should be provided with supplemental funding to enable them to extend coverage 
of COVID-19 control, including the rapid scale-up of vaccination programs. 
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Sustainable Development Solutions Network  
Dr. Michel Sidibe, African Union Special Envoy for the African Medicines Agency (AMA); for-
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